|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.08.26 - 15:06
|
WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds (SCMP)
|
|
|
WuXi Biologics, one of China's largest contract drug developers, posted a 4.3 per cent increase in profit attributable to shareholders in the first half of the year, as stronger demand and improved capacity utilisation lifted revenue and margins.
The Wuxi, Jiangsu-based company's net profit attributable to shareholders rose to 2.44 billion yuan (US$363 million) in the six months ended June, according to its filing to the Hong Kong stock exchange on Tuesday. Revenue increased 18.4 per cent to......
|
|
|
|
|
|
|
|
|
|